Metabolism and cardiovascular system
Carbohydrates, lipids, endothelium and liver: the area where you measure whether an ingredient really affects the mechanisms behind metabolic and cardiovascular wellbeing.
Physiological areas
GastrointestinalMetabolism and cardiovascular systemDermatologicalNeurologicalOphthalmicMusculoskeletalRespiratoryOralUrologicalVaginalImmune systemWhat you can demonstrate here
If your product targets glycaemic control, the lipid profile, vascular protection or liver function, this is where the evidence supporting that promise is built. These are the mechanisms where the market is most crowded and most demanding: a comparative figure, on a relevant cell model, is what separates an ingredient from its competitor.
The models we use
What we measure
- Inhibition of alpha-amylase and alpha-glucosidase
- Glucose uptake in hepatocytes and adipocytes
- Anti-glycation activity
- GLP-1, GIP and PYY secretion from enteroendocrine cells
- DPP-4 inhibition, cell-free and on intestinal epithelium
- Glucose-stimulated insulin secretion by pancreatic beta cells treated with the digested ingredient
- The path is staged: the pancreas axis or the microbiota arm starts only if the first phase passes an efficacy threshold agreed in advance.
- Insulin-resistance models on hepatocytes, skeletal muscle cells and adipocytes, induced by excess lipids, glucose or inflammation
- Insulin-stimulated glucose uptake, insulin signalling (Akt phosphorylation), GLUT4 translocation, lipid accumulation
- In the liver model we also measure glucose production and release: in hepatocytes glucose transport is not directly insulin-dependent, so uptake alone does not show resistance
- Analysis of LDL receptors in hepatocytes
- HMG-CoA reductase inhibition
- Inhibition of LDL oxidation
- Anti-lipogenic activity and fatty acid oxidation
- Anti-inflammatory activity on endothelial cells
- Cytoprotection of the endothelium from oxidative stress
- Nitric oxide production
- Vessel integrity and permeability in an in vitro model
- Tubulogenesis and capillary reorganisation
- Viability and cytoprotection of hepatocytes
- Antioxidant activity in liver cells
What is measured in this area
Carbohydrates, lipids, endothelium and liver: the endpoints that show whether an ingredient acts on the mechanisms behind metabolic and cardiovascular wellbeing.
- GLP-1, GIP and PYY secretion — the signal the gut sends the pancreas that glucose is arriving
- DPP-4 inhibition — the enzyme that degrades GLP-1 and GIP
- Insulin sensitivity — how liver, muscle and adipose tissue respond to insulin
- Glucose uptake — glucose entering the cell, with and without stimulus
- Lipid accumulation — lipids accumulated in adipocytes, quantified rather than estimated
- Adipogenesis and lipolysis — adipocyte differentiation and lipid mobilisation
- Endothelial function — endothelial cell response and nitric oxide production
- Vascular oxidative stress — reactive species generated on the endothelium under stimulus
- Inflammatory markers — cytokines released by endothelium and adipose tissue
- Lipid metabolism enzymes — activity on lipases and on the enzymes involved in synthesis
- Liver models — hepatocyte viability and function under the conditions tested
What you receive
- A report with model, protocol, controls and raw data
- Results per replicate, with mean and spread declared
- Concentration-response curves on the chosen endpoints
- A comparison between the stimulated condition and the control, which is the data that holds
- A readable comparison between the conditions tested, usable in a technical dossier or in a conversation with a downstream customer
Who it is for, and where to start
- You are choosing between raw materials and need a measured criterion: ingredient validation and valorisation
- You have a finished product and want to know how much stays active in the formulation: supplement valorisation
- You need an ingredient that does not exist yet for this function: development of new ingredients
